High-dose Methotrexate with Citrovorum Factor Rescue in Non-small-cell Lung Cancer

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1978 Jan 1

PMID 373922

Citations 1

Authors

F A Greco

M F Fer

R L Richardson

K R Hande

C J van Boxtel

R K Oldham

Affiliations

Soon will be listed here.

Abstract

Nineteen patients with non-small-cell carcinoma of the lung were treated with high-dose methotrexate and leucovorin rescue. Two partial responses (10.5%) were observed, lasting 13 and 17 weeks. Toxicity was acceptable. It is concluded that the occasional benefit of high-dose methotrexate with leucovorin rescue at this dose and according to the schedule described for these patients does not warrant further study.

Citing Articles

Combination chemotherapy (high-dose methotrexate with citrovorum factor rescue, mechlorethamine, and procarbazine) in non-small cell lung cancer.

Bhasin R, Nogeirie C Cancer Chemother Pharmacol. 1983; 11(2):106-7.

PMID: 6605217 DOI: 10.1007/BF00254256.

References

Bunn Jr P, Cohen M, Ihde D, Fossieck Jr B, Matthews M, Minna J . Advances in small cell bronchogenic carcinoma. Cancer Treat Rep. 1977; 61(3):333-42. View

Goldin A, Mantel N, GREENHOUSE S, Venditti J, HUMPHREYS S . Estimation of the antileukemic potency of the antimetabolite aminopterin, administered alone and in combination with citrovorum factor or folic acid. Cancer Res. 1953; 13(12):843-50. View

Bertino J . "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. Semin Oncol. 1977; 4(2):203-16. View

Myers C, Lippman M, Elliot H, Chabner B . Competitive protein binding assay for methotrexate. Proc Natl Acad Sci U S A. 1975; 72(9):3683-6. PMC: 433061. DOI: 10.1073/pnas.72.9.3683. View

Goldman I, Fyfe M . The mechanism of action of methotrexate. II. Augmentation by vincristine of inhibition of deoxyribonucleic aic synthesis by methotrexate in Ehrlich ascites tumor cells. Mol Pharmacol. 1974; 10(2):275-82. View

. Third national cancer survey: incidence data. Natl Cancer Inst Monogr. 1975; (41):i-x, 1-454. View

Jaffe N, Frei 3rd E, Traggis D, Bishop Y . Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med. 1974; 291(19):994-7. DOI: 10.1056/NEJM197411072911902. View

Eagan R, Ingle J, Frytak S, Rubin J, Kvols L, CARR D . Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. Cancer Treat Rep. 1977; 61(7):1339-45. View

CAPIZZI R, DeConti R, Marsh J, Bertino J . Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue". Cancer Res. 1970; 30(6):1782-8. View

10.

Greco F, Richardson R, Schulman S, Stroup S, Oldham R . Treatment of oat cell carcinoma of the lung: complete remissions, acceptable complications, and improved survival. Br Med J. 1978; 2(6129):10-1. PMC: 1605667. DOI: 10.1136/bmj.2.6129.10. View

11.

Stoller R, Hande K, Jacobs S, Rosenberg S, Chabner B . Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977; 297(12):630-4. DOI: 10.1056/NEJM197709222971203. View

12.

Djerassi I, ROMINGER C, Kim J, Turchi J, Suvansri U, Hughes D . Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer. Cancer. 1972; 30(1):22-30. DOI: 10.1002/1097-0142(197207)30:1<22::aid-cncr2820300105>3.0.co;2-b. View